Article

Direct Evidence for Epithelial-Mesenchymal Transitions in Breast Cancer

Department of Molecular Genetics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Cancer Research (Impact Factor: 9.33). 03/2008; 68(3):937-45. DOI: 10.1158/0008-5472.CAN-07-2148
Source: PubMed

ABSTRACT

We developed stromal- and epithelial-specific cre-transgenic mice to directly visualize epithelial-mesenchymal transition (EMT) during cancer progression in vivo. Using three different oncogene-driven mouse mammary tumor models and cell-fate mapping strategies, we show in vivo evidence for the existence of EMT in breast cancer and show that myc can specifically elicit this process. Hierarchical cluster analysis of genome-wide loss of heterozygosity reveals that the incidence of EMT in invasive human breast carcinomas is rare, but when it occurs it is associated with the amplification of MYC. These data provide the first direct evidence for EMT in breast cancer and suggest that its development is favored by myc-initiated events.

Download full-text

Full-text

Available from: Michael C Ostrowski
    • "Also, cancer cell migration and invasion were comparable (Figures 2E–2L). Since previous studies documented only minimal EMT in MMTV-PyMT tumors (Trimboli et al., 2008), we investigated other mechanisms via which PHD2 haplodeficiency reduced intravasation and dissemination. PHD2 Haplodeficiency in Cancer Cells Does Not Affect Cancer-Cell-Intrinsic Invasive Properties but Reduces Metastasis To assess the role of PHD2 in cancer cells, we generated mice in which one PHD2 allele was deleted in cancer cells by intercrossing PHD2 +/lox mice with MMTV-Cre mice and then with "
    [Show abstract] [Hide abstract]
    ABSTRACT: Several questions about the role of the oxygen sensor prolyl-hydroxylase 2 (PHD2) in cancer have not been addressed. First, the role of PHD2 in metastasis has not been studied in a spontaneous tumor model. Here, we show that global PHD2 haplodeficiency reduced metastasis without affecting tumor growth. Second, it is unknown whether PHD2 regulates cancer by affecting cancer-associated fibroblasts (CAFs). We show that PHD2 haplodeficiency reduced metastasis via two mechanisms: (1) by decreasing CAF activation, matrix production, and contraction by CAFs, an effect that surprisingly relied on PHD2 deletion in cancer cells, but not in CAFs; and (2) by improving tumor vessel normalization. Third, the effect of concomitant PHD2 inhibition in malignant and stromal cells (mimicking PHD2 inhibitor treatment) is unknown. We show that global PHD2 haplodeficiency, induced not only before but also after tumor onset, impaired metastasis. These findings warrant investigation of PHD2's therapeutic potential. Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
    No preview · Article · Jul 2015 · Cell Reports
  • Source
    • "Although type III EMT is far different from those observed in the other two types of EMT, the MT I and III have the association to some extent. Recent human studies found once the migratory cancer cells generated by type III EMT find themselves in distant tissue beds, and then they form secondary tumors exhibiting an epithelial phenotype (Brabletz et al., 2001;Rastaldi et al., 2002;Bataille et al., 2008;Reckamp et al., 2008;Trimboli et al., 2008). This suggests that the reversibility of EMT observed during embryonic development , when migratory mesenchyme gives rise to secondary epithelia, is also operational in the formation of secondary metastatic nodule. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Sorafenib has been used as an oral anti-cancer drug because of its ability to inhibit tumor growth. However, the pharmacological effect of sorafenib is still the lack of in vivo experimental evidence. Tumor and embryonic cells share some similar features, so we investigated the effects of sorafenib on the development of gastrulating chick embryos. We found that sorafenib exposure was markedly attributed to the number of embryonic cell in proliferation and apoptosis. We also detected sorafenib significantly interfered with epithelial-mesenchymal transition (EMT). Furthermore, sorafenib treatment impaired the production and migration of neural crest cells. This article is protected by copyright. All rights reserved. © 2015 Wiley Periodicals, Inc.
    Full-text · Article · Mar 2015 · The Anatomical Record Advances in Integrative Anatomy and Evolutionary Biology
  • Source
    • "In vitro studies have also shown NEU to act as an active rat mammary gland genotoxic carcinogen [4,49]. During the process of neoplastic transformation, one of the earliest stages of invasion is epithelial to mesenchymal transition (EMT) wherein the epithelial cells acquire mesenchymal characteristic so as to invade the surrounding extracellular matrix and migrate towards distant organs [50,51]. EMT is characterised by loss of polarity of the epithelial cells, appearance of mesenchymal markers (upregulation of vimentin, fibronectin, N-cadherin) and down regulation of the epithelial markers (E-cadherin, occludins, cytokeratin 19, claudins) [52,53]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The DNA damage checkpoint signalling cascade sense damaged DNA and coordinates cell cycle arrest, DNA repair, and/or apoptosis. However, it is still not well understood how the signalling system differentiates between different kinds of DNA damage. N-nitroso-N-ethylurea (NEU), a DNA ethylating agent induces both transversions and transition mutations. Immunoblot and comet assays were performed to detect DNA breaks and activation of the canonical checkpoint signalling kinases following NEU damage upto 2 hours. To investigate whether mismatch repair played a role in checkpoint activation, knock-down studies were performed while flow cytometry analysis was done to understand whether the activation of the checkpoint kinases was cell cycle phase specific. Finally, breast epithelial cells were grown as 3-dimensional spheroid cultures to study whether NEU can induce upregulation of vimentin as well as disrupt cell polarity of the breast acini, thus causing transformation of epithelial cells in culture. We report a novel finding that NEU causes activation of major checkpoint signalling kinases, Chk1 and Chk2. This activation is temporally controlled with Chk2 activation preceding Chk1 phosphorylation, and absence of cross talk between the two parallel signalling pathways, ATM and ATR. Damage caused by NEU leads to the temporal formation of both double strand and single strand breaks. Activation of checkpoints following NEU damage is cell cycle phase dependent wherein Chk2 is primarily activated during G2-M phase whilst in S phase, there is immediate Chk1 phosphorylation and delayed Chk2 response. Surprisingly, the mismatch repair system does not play a role in checkpoint activation, at doses and duration of NEU used in the experiments. Interestingly, NEU caused disruption of the well-formed polarised spheroid archithecture and upregulation of vimentin in three-dimensional breast acini cultures of non-malignant breast epithelial cells upon NEU treatment indicating NEU to have the potential to cause early transformation in the cells. NEU causes damage in mammalian cells in the form of double strand and single strand breaks that temporally activate the major checkpoint signalling kinases without the occurrence of cross-talk between the pathways. NEU also appear to cause transformation in three-dimensional spheroid cultures.
    Full-text · Article · Apr 2014 · BMC Cancer
Show more